Boston Scientific (BSX) Stock Overview
Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BSX Community Fair Values
Create NarrativeSee what 202 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Boston Scientific
55.6% undervalued intrinsic discount
BSX after Penumbra ?
View narrativeBI
Published 25 Jan
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.87 |
| 52 Week High | US$105.65 |
| 52 Week Low | US$42.20 |
| Beta | 0.57 |
| 1 Month Change | -15.36% |
| 3 Month Change | -2.40% |
| 1 Year Change | -55.68% |
| 3 Year Change | -17.27% |
| 5 Year Change | 1.18% |
| Change since IPO | 924.70% |
Recent News & Updates
Seeking Alpha • Sep 11
Boston Scientific: $43 Finally Prices In A Bad 2026
Summary Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns. Read the full article on Seeking Alpha
Narrative Update • Sep 08
BSX: Shipping Restoration And Reset Expectations Will Set Stage For Recovery
Analysts have trimmed the fair value estimate for Boston Scientific from about $96.91 to $82.81. This reflects a broad reset in price targets after updated guidance for growth, margins and future P/E assumptions, even as recent research points to restored shipping capabilities and ongoing confidence in the company’s longer term product pipeline.
Narrative Update • Aug 25
BSX: Long-Term Pipeline Will Offset Watchman And Electrophysiology Headwinds
Analysts have reset expectations for Boston Scientific, cutting the consolidated price target to approximately $62.69 from $72.25 as they factor in reduced long term growth assumptions and a lower future P/E multiple, despite ongoing support for the stock from many firms. Analyst Commentary Street research on Boston Scientific now reflects a reset in expectations, but not a loss of interest in the stock.Recent updates
Seeking Alpha • Sep 11
Boston Scientific: $43 Finally Prices In A Bad 2026
Summary Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns. Read the full article on Seeking AlphaNarrative Update • Sep 08
BSX: Shipping Restoration And Reset Expectations Will Set Stage For Recovery
Analysts have trimmed the fair value estimate for Boston Scientific from about $96.91 to $82.81. This reflects a broad reset in price targets after updated guidance for growth, margins and future P/E assumptions, even as recent research points to restored shipping capabilities and ongoing confidence in the company’s longer term product pipeline.Narrative Update • Aug 25
BSX: Long-Term Pipeline Will Offset Watchman And Electrophysiology Headwinds
Analysts have reset expectations for Boston Scientific, cutting the consolidated price target to approximately $62.69 from $72.25 as they factor in reduced long term growth assumptions and a lower future P/E multiple, despite ongoing support for the stock from many firms. Analyst Commentary Street research on Boston Scientific now reflects a reset in expectations, but not a loss of interest in the stock.
Narrative Update • Aug 11
BSX: Electrophysiology And Watchman Headwinds Will Pressure Future Returns
Analysts have cut their price targets on Boston Scientific in recent months, and the model fair value estimate has been reduced from $69.00 to $44.00 as expectations reset around slower revenue growth, slightly lower profit margins, a reduced future P/E, and updated guidance on key products like Watchman and electrophysiology. Analyst Commentary Recent Street research on Boston Scientific points to a clear reset in expectations.Analysis Article • Aug 07
Boston Scientific Corporation (NYSE:BSX) Just Reported, And Analysts Assigned A US$62.69 Price Target
Investors in Boston Scientific Corporation ( NYSE:BSX ) had a good week, as its shares rose 7.2% to close at US$49.30...Narrative Update • Jul 28
BSX: Long-Term Pipeline And Buybacks Will Counter Watchman Uncertainty
Boston Scientific's updated analyst price target of $72.25, compared with the prior $75.00 fair value estimate, reflects a broad wave of Street target cuts as analysts factor in softer Watchman and electrophysiology expectations, while still pointing to intact fundamentals and underappreciated growth areas. Analyst Commentary Recent Street research on Boston Scientific points to a reset in expectations around Watchman and electrophysiology, while still highlighting core strengths in the broader portfolio.Narrative Update • Jul 14
BSX: Reset Growth Expectations Will Set Stage For Future Recovery Potential
Analyst price targets for Boston Scientific have been revised downward by roughly $25 to $30 as analysts factor in softer Watchman growth, ongoing electrophysiology headwinds, and slightly more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research on Boston Scientific points to a mixed but still constructive backdrop, with many firms trimming price targets while maintaining positive ratings.Narrative Update • Jun 30
BSX: Clinical Pipeline Strength Will Offset Watchman Reset And Sector Headwinds
The analyst price target for Boston Scientific has been reduced by $2.10, from $77.10 to $75.00, as analysts factor in slower Watchman growth, lower utilization trends, and more conservative long term revenue and margin assumptions across the medtech sector. Analyst Commentary Recent research on Boston Scientific points to a clear split between optimism on the broader business and caution around Watchman and utilization trends.Analysis Article • Jun 19
Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance
Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...Narrative Update • Jun 16
BSX: Clinical Pipeline And Share Repurchases Will Support Rebased Expectations
Boston Scientific's fair value estimate has been trimmed from $79.40 to $77.10, as analysts lower price targets across the sector and factor in slower Watchman growth, a more cautious utilization backdrop, and slightly reduced long term revenue and margin assumptions. Analyst Commentary Recent Street research on Boston Scientific clusters around a similar theme, with most firms trimming price targets and revisiting assumptions on growth, margins, and valuation after the latest Watchman commentary and a softer utilization backdrop.Narrative Update • Jun 01
BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations
Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.Narrative Update • May 08
BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations
Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.New Narrative • Apr 24
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 22
BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns
Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.New Narrative • Apr 08
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 07
BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns
Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.Narrative Update • Mar 24
BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines
Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.Narrative Update • Mar 08
BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound
Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.Narrative Update • Feb 22
BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize
Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.Narrative Update • Feb 06
BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize
The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
New Narrative • Jan 25
BSX after Penumbra ?
The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Narrative Update • Jan 10
BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential
Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.Narrative Update • Dec 25
BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan
Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.Narrative Update • Dec 11
BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum
Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.Narrative Update • Nov 27
BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum
Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.Narrative Update • Nov 07
BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence
Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.Narrative Update • Oct 24
Future Growth Plans And Acquisitions Will Drive Broader Market Expansion
Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.Shareholder Returns
| BSX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.5% | -0.4% | -1.6% |
| 1Y | -55.7% | -16.3% | 12.1% |
Return vs Industry: BSX underperformed the US Medical Equipment industry which returned -16.3% over the past year.
Return vs Market: BSX underperformed the US Market which returned 12.1% over the past year.
Price Volatility
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BSX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BSX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 59,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
Boston Scientific Corporation Fundamentals Summary
| BSX fundamental statistics | |
|---|---|
| Market cap | US$65.29b |
| Earnings (TTM) | US$3.67b |
| Revenue (TTM) | US$21.00b |
17.3x
P/E Ratio3.0x
P/S RatioIs BSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSX income statement (TTM) | |
|---|---|
| Revenue | US$21.00b |
| Cost of Revenue | US$6.47b |
| Gross Profit | US$14.53b |
| Other Expenses | US$10.85b |
| Earnings | US$3.67b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Oct 28, 2026
| Earnings per share (EPS) | 2.54 |
| Gross Margin | 69.19% |
| Net Profit Margin | 17.50% |
| Debt/Equity Ratio | 49.7% |
How did BSX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 03:54 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boston Scientific Corporation is covered by 58 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| null null | Baird |